EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Durable Response After Pembrolizumab for Recurrent Tracheal Squamous Cell Carcinoma: A Case Report and Focused Literature Review

Sreoshy Saha, Jongyeob Kim, Inae Park, Nitika Paudel, Jay C Zeck, Peter J Bergquist, Rebecca Krochmal, Chul Kim

Clinical Lung Cancer · 2026-11 · 27 (9) · 34-38

DOI: 10.1016/j.cllc.2026.09.005 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Lung Cancer, 2026-11. Verfasst von Sreoshy Saha und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mymensingh Medical College Hospital, Mymensingh, Bangladesh. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Georgetown Lombardi Comprehensive Cancer Center.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary tracheal squamous cell carcinoma (SCC) is rare, and the role of immune checkpoint inhibition in recurrent or unresectable disease remains poorly defined. We report a 51-year-old woman with a presumed late local recurrence of tracheal SCC approximately 7 years after initial diagnosis and 6 years after definitive chemoradiotherapy. She presented with dyspnea and episodic choking, and imaging demonstrated a localized distal tracheal recurrence. Multidisciplinary evaluation determined that salvage surgery and re-irradiation carried substantial morbidity because of the tumor location and prior radiation exposure. Bronchoscopic debulking achieved partial tumor removal, but residual metabolically active disease remained, with a maximum SUV of 15.7 on PET/CT and no distant metastases. Histology confirmed moderately-to-poorly differentiated SCC with focal keratinization. Molecular profiling demonstrated PD-L1 expression of 15% by 22C3 TPS, TMB of 13 mutations/Mb, and microsatellite-stable disease. Pembrolizumab monotherapy was initiated. After approximately 2 months, CT demonstrated marked reduction of the endotracheal lesion, accompanied by resolution of her respiratory symptoms. CT performed approximately 22 months after treatment initiation demonstrated sustained partial response. She completed approximately 2 years of pembrolizumab treatment without immune-related adverse events. A focused literature review identified five previously reported cases of ICI-treated tracheal SCC, including responses to pembrolizumab, nivolumab, and durvalumab across heterogeneous clinical settings. This case report and focused literature review highlights the potential role of ICI-based treatment in tracheal SCC and supports consideration of ICIs in selected patients with recurrent or unresectable disease when conventional treatment options are limited. At the same time, it underscores the need for multicenter registries and collaborative efforts to better define patient selection, treatment sequencing, and long-term outcome.

Autor:innen und Institutionen

  • Department of Internal Medicine, Mymensingh Medical College Hospital, Mymensingh, Bangladesh.
  • Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
  • Department of Internal Medicine, Montefiore Medical Center, Bronx, NY.
  • Department of Radiation Oncology, Medstar Georgetown University Hospital, Washington, DC.
  • Department of Pathology and Laboratory Medicine, Medstar Georgetown University Hospital, Washington, DC.
  • Department of Radiology, Medstar Georgetown University Hospital, Washington, DC.

Förderung

  • Georgetown Lombardi Comprehensive Cancer Center

Zitieren

APA

Saha, S., Kim, J., Park, I., Paudel, N., Zeck, J. C., Bergquist, P. J., Krochmal, R., & Kim, C. (2026). Durable Response After Pembrolizumab for Recurrent Tracheal Squamous Cell Carcinoma: A Case Report and Focused Literature Review. Clinical Lung Cancer, 27(9), 34-38. https://doi.org/10.1016/j.cllc.2026.09.005

Vancouver

Saha S, Kim J, Park I, Paudel N, Zeck JC, Bergquist PJ, et al. Durable Response After Pembrolizumab for Recurrent Tracheal Squamous Cell Carcinoma: A Case Report and Focused Literature Review. Clinical Lung Cancer. 2026;27(9):34-38. doi:10.1016/j.cllc.2026.09.005

BibTeX
@article{Saha2026,
  author = {Saha, Sreoshy and Kim, Jongyeob and Park, Inae and Paudel, Nitika and Zeck, Jay C and Bergquist, Peter J and Krochmal, Rebecca and Kim, Chul},
  title = {Durable Response After Pembrolizumab for Recurrent Tracheal Squamous Cell Carcinoma: A Case Report and Focused Literature Review},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {34--38},
  doi = {10.1016/j.cllc.2026.09.005}
}
Kostenlos starten →